Validation of Current Good Manufacturing Practice Compliant Human Pluripotent Stem Cell-Derived Hepatocytes for Cell-Based Therapy by Blackford, Samuel John Irwin et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1002/sctm.18-0084
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Blackford, S. J. I., Ng, S. S., Segal, J. M., King, A., Austin, A. L. F., Kent, D. H., ... Rashid, S. T. (2019).
Validation of Current Good Manufacturing Practice Compliant Human Pluripotent Stem Cell-Derived
Hepatocytes for Cell-Based Therapy. Stem cells translational medicine, 8(2), 124-137.
https://doi.org/10.1002/sctm.18-0084
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 09. Jul. 2020
Validation of Current Good Manufacturing Practice
Compliant Human Pluripotent Stem Cell-Derived
Hepatocytes for Cell-Based Therapy
SAMUEL J.I. BLACKFORD,a,* SOON SENG NG ,a,* JOE M. SEGAL,a AILEEN J.F. KING,c
AMAZON L. AUSTIN,c DENIZ KENT,a JENNIFER MOORE,d MICHAEL SHELDON,d DUSKO ILIC ,e
ANIL DHAWAN,b RAGAI R. MITRY,b S. TAMIR RASHIDa,b
Key Words. Pluripotent stem cells • Hepatocytes • cGMP • Bioengineering • Liver therapy •
iPSC • hESC • Hepatocyte differentiation • Cell transplantation • Cellular therapy
ABSTRACT
Recent advancements in the production of hepatocytes from human pluripotent stem cells
(hPSC-Heps) afford tremendous possibilities for treatment of patients with liver disease. Vali-
dated current good manufacturing practice (cGMP) lines are an essential prerequisite for such
applications but have only recently been established. Whether such cGMP lines are capable of
hepatic differentiation is not known. To address this knowledge gap, we examined the proficiency
of three recently derived cGMP lines (two hiPSC and one hESC) to differentiate into hepatocytes
and their suitability for therapy. hPSC-Heps generated using a chemically defined four-step hepatic
differentiation protocol uniformly demonstrated highly reproducible phenotypes and functional-
ity. Seeding into a 3D poly(ethylene glycol)-diacrylate fabricated inverted colloid crystal scaffold
converted these immature progenitors into more advanced hepatic tissue structures. Hepatic
constructs could also be successfully encapsulated into the immune-privileged material alginate
and remained viable as well as functional upon transplantation into immune competent mice.
This is the first report we are aware of demonstrating cGMP-compliant hPSCs can generate cells
with advanced hepatic function potentially suitable for future therapeutic applications. STEM
CELLS TRANSLATIONAL MEDICINE 2019;8:124–137
SIGNIFICANCE STATEMENT
Current good manufacturing practice (cGMP) compliant human pluripotent stem cells (hPSC)
have been recently established for clinical application. To validate the capability of such cGMP
lines for liver therapy, this article describes their proficiency on advanced hepatocyte production
using both conventional culture plate and three-dimensional hydrogel systems. The subsequent
study on hepatocyte transplantation into immune competent mice using alginate encapsulation
model further demonstrates the suitability of cGMP hPSC-derived hepatocytes for cell-based
therapy. To the authors’ knowledge, this is the first report demonstrating that cGMP-compliant
hPSCs can generate cells with advanced hepatic function potentially suitable for future thera-
peutic applications.
INTRODUCTION
For patient’s presenting with end-stage chronic
liver disease or acute liver failure (ALF), orthoto-
pic transplantation of a donor liver remains
the only curative treatment. Due to lengthening
waiting lists and a severe scarcity of donors,
mortality rates are increasing annually [1]. As a
result, an alternative strategy for treating these
patients is urgently required. Allogenic trans-
plantation of primary adult hepatocytes, the
major functional cell-type of the liver, is consid-
ered a viable solution in certain clinical indications
[2–4]. Lack of sufficient numbers of high-quality
hepatocytes; a result of isolating cells from tissue
deemed unsuitable for transplantation, has lim-
ited the success of this programme [5, 6]. Deriva-
tion of human embryonic stem cells (hESCs) [7]
and their related induced pluripotent stem cells
(hiPSCs) [8, 9], however, has generated growing
optimism that the development of cellular ther-
apies, such as would be suitable for liver dis-
ease, is finally an obtainable goal [10]. Unlike
primary hepatocytes, which cannot be cultured
or expanded in vitro [11, 12], human pluripo-
tent stem cells (hPSCs) possess an unlimited
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ability for self-renewal [13]. This capability to produce large
batches of cells is of clinical significance as hepatocyte numbers
approaching 8 billion may be required for transplant when cor-
recting metabolic liver function in pediatric patients [14], or
15 billion to support liver failure in adults [15]. Studies have
shown that both hESCs [16, 17] and hiPSCs [18–20] can be dif-
ferentiated into hepatocytes (hPSC-Heps), sharing functional
attributes of their in vivo equivalents, including albumin/α-1
antitrypsin (A1AT) protein secretion, cytochrome P450 activity
and glycogen storage. As research tools, hPSCs have delivered
novel insights into human hepatic development [21], the crea-
tion of liver disease models [22, 23], and provided new plat-
forms for pharmacological testing [24]. Furthermore, the
successful, albeit limited, repopulation of rodent livers follow-
ing transplantation of both hESC, and hiPSC-derived hepato-
cytes has been reported by several groups [25–27], suggesting
hPSC-Heps may be a viable treatment option for patients with
liver disease.
The stem cell field has developed at an exceptional rate,
which has resulted in the first human trials using cells derived
from hESCs/hiPSCs being undertaken [28–32]. Although approved
for clinical use, these lines were in fact developed for research
purposes and not produced under current good manufacturing
practice (cGMP) guidelines. These manufacturing regulations for
stem cell therapy products are described by the Food and Drug
Administration in the U.S., and since the 2004 European Union
Tissues and Cells Directive, the European Medicines Agency
within the European Union. Generating cells under cGMP condi-
tions ensures their clinical safety, and for cellular therapies should
be differentiated in fully defined, xeno-free conditions [33] to
ensure reproducibility, and prevent xeno-mediated infection or
immune rejection [34].
In 2011, scientists from King’s College London submitted
the first xeno-free clinical grade hESCs [35] to the U.K. Stem
Cell Bank [36]. More recently, cGMP-compliant hiPSCs have
been generated by teams in People’s Republic of China [37],
Japan [38], the U.S. [39] and the U.K. [40]. These clinically
compliant lines have been extensively characterized as pluripo-
tent with profiles comparable to previously validated hPSCs
derived outside of these manufacturing guidelines [41]. How-
ever, given previous reports describing the varied potential for
hPSC lines to differentiate into target cell types [42–44], evalu-
ation of their hepatic differentiation potential represents an
essential prerequisite to further clinical development work.
The objective of this study was therefore to undertake this
evaluation and then test the potential of differentiated cells to
be engineered into three-dimensional (3D) constructs suitable
for clinical application.
MATERIALS AND METHODS
Cell Lines and Cell Culture
Two cGMP hiPSC lines (CGT-RCiB-10 [line 1; Cell & Gene Ther-
apy Catapult, London, U.K.] and LiPSC-GR1.1 [line 2; Lonza,
Walkersville, MD]) and one cGMP hESC line (KCL037 [line 3;
Gifted from D. Ilic, King’s College London]) were used in this
study. All three lines were recovered into the culture conditions
recommended by their respective suppliers. After two pas-
sages, each of the lines was subsequently maintained on Vitro-
nectin XF (STEMCELL Technologies, Vancouver, BC, Canada)
coated Corning Costar TC-treated 6-well plates (Sigma–Aldrich,
St. Louis, MO) in TeSR-E8 (STEMCELL Technologies, Vancouver,
BC, Canada) and passaged every 4 days using Gentle Cell Disso-
ciation Reagent (STEMCELL Technologies). Line 3 was passaged
in TeSR-8 supplemented with 10 μM Y-27632 dihydrochloride
(R&D Systems, Minneapolis, MN) to ensure cell survival.
Hepatocyte differentiation was carried out in Essential
6 Medium (Thermo Fisher Scientific, Waltham, MA; days 1–2),
RPMI-1640 Medium (Sigma–Aldrich; days 3–8) and HepatoZYME-
SFM (Thermo Fisher Scientific; day 9 onward) within Corning
Falcon 100 × 20 mm style tissue culture dishes (Sigma–
Aldrich). The following growth factors and small molecules
were supplemented into the media for hepatocyte differentia-
tion as shown in Figure 1A: 3 μM CHIR9901 (Sigma–Aldrich),
10 ng/ml BMP4 (R&D Systems), 10 μM LY29004 (Promega,
Madison, WI), 80 ng/ml FGF2 (R&D Systems), 100 ng/ml and
50 ng/ml day 4 onward Activin A (Qkine, Cambridge, U.K.),
10 ng/ml OSM (R&D Systems) and 50 ng/ml HGF (PeproTech,
Rocky Hill, NJ). Day 21 hPSC-Heps were dissociated into a
single-cell suspension using TrypLE Express Enzyme (1×), no
phenol red (Thermo Fisher Scientific).
Brightfield and Immunofluorescence Imaging
Brightfield microscopy was performed on a Leica DMIL LED
inverted microscope and imaged using the Leica DFC3000 G
camera (Leica Microsystems, Wetzlar, Germany).
For immunofluorescence staining, samples were fixed for
10 minutes with 4% wt/vol paraformaldehyde, and then blocked
and permeabilized in 1% wt/vol bovine serum albumin (Sigma–
Aldrich), 3% donkey serum (Thermo Fisher Scientific) and 0.1%
Triton X-100 (Sigma–Aldrich). An additional 10 minutes of per-
meabilisation was performed using 0.5% Triton X-100 for detec-
tion of nuclear antigens. Primary antibodies were applied for
1 hour and after wash steps Alexa Fluor-555/488 conjugated
secondary antibodies (Thermo Fisher Scientific) were incu-
bated for 40 minutes. NucBlue Fixed Cell ReadyProdes Reagent
(Thermo Fisher Scientific) was applied for visualization of cell
nuclei. Imaging for two-dimensional (2D) culture was per-
formed on an Operetta High Content Screening System
(PerkinElmer, Waltham, MA), and for 3D culture, a Nikon
Eclipse Ti inverted spinning disk confocal microscope (Nikon,
Minto, Japan).
Real-Time PCR
Total RNA was isolated using the RNeasy Mini Kit (QIAGEN,
Hilden, Germany) according to manufacturer’s protocol. RNA
was quantified spectrophotometrically using the NanoDrop
2000 (Thermo Fisher Scientific). Three hundred and fifty nano-
grams of total RNA was used to produce first-strand cDNA
using the SuperScript VILO cDNA synthesis kit (Thermo Fisher
Scientific). Quantitative real-time PCR (RT-PCR) was performed
in a 10 μl reaction mixture consisting of cDNA, custom
designed oligonucleotide primers (Sigma–Aldrich) and Fast
SYBR Green PCR Master Mix (Thermo Fisher Scientific), on a
CFX384 Touch Real-Time PCR Detection System (Bio-Rad, Hercu-
les, CA). ACTB mRNA was used for housekeeping normalization.
Flow Cytometric Analysis
Adherent cells were dissociated into a single-cell suspension
using TrypLE Express Enzyme (1×), no phenol red, and subse-
quently treated for 30 minutes with LIVE/DEAD Fixable Cell
Stain (Thermo Fisher Scientific) and then fixed using 4% wt/vol
www.StemCellsTM.com © 2018 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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paraformaladehyde (PFA) for 10 minutes. Cells were incubated
with fluorophore-conjugated antibodies for 30 minutes in the
dark, and then washed twice with phosphate buffered solution
(PBS). Immunophenotyping was carried out using the BD FACS-
Canto II system (Becton Dickinson, Franklin Lakes, NJ) and ana-
lyzed using FlowJo software (Becton Dickinson).
Assessment of Hepatic Function
Albumin production of hPSC-Heps was measured using the
Human Albumin Quantification Set (Bethyl Laboratories, Mont-
gomery, AL). Culture medium supernatants were collected after
48 hours and stored at −20C. Enzyme-linked immunosorbent
assay (ELISA) was carried out according to manufacturer’s
instructions. Absorbance was measured at 450 nm on a Pro-
mega GloMax Multi+ Detection System plate reader (Promega).
Native cytochrome P450 CYP3A4 activity was assessed
using the CYP3A4 P450-Glo Assay with Luciferin-IPA (Promega).
The bioluminescent substrate was incubated on hPSC-Heps for
1 hour before being collected for analysis. Luminescence was
measured using a Promega GloMax Discover multimode micro-
plate reader (Promega).
Fabrication of ICC PEG-DA Scaffolds
Thermo Scientific 4,000 Series monosized polystyrene beads of
100  1.5 μm diameter (Thermo Fisher Scientific) were sus-
pended in 70% EtOH and agitated using an ultrasonic bath.
The dispersed bead suspension was seeded into hexagonal
polypropylene molds and left to dry overnight on an orbital
shaker.
A self-standing colloidal crystal lattice was produced through
annealing the beads at 120C for 4 hours. Poly(ethylene glycol)-
diacrylate (PEG-DA; Thermo Fisher Scientific) acrylate-PEGN-
hydroxysuccinimide (Laysan Bio Inc., Arab) and Irgacure 2,959
photoinitiator (BASF, London, U.K.) were mixed together in
dH20 at a concentration of 50%, 10%, and 1% wt/vol, respec-
tively. The bead lattices were placed within this precursor solu-
tion, and centrifugation (500g, 5 minutes) was performed to
ensure complete infiltration. Hydrogel fabrication was com-
pleted through UV light induced gelation of the precursor solu-
tion and the polystyrene crystal lattice was removed from the
scaffold through tetrahydrofuran (Sigma–Aldrich) soaking for
4 hours.
Generation of hPSC-Derived Hepatocyte Spheroids
A single cell suspension of day 21 hPSC-Heps was prepared
and 0.3 × 106 cells were seeded per well of a 24-well
Aggrewell-400 (STEMCELL Technologies). Aggrewell plates
were prepared as recommended by the supplier. Centrifuga-
tion at 200g for 3 minutes was carried out to deposit cells into
the microwells of the plate.
Alginate Encapsulation of hPSC-Derived Hepatocyte
Spheroids
Encapsulation was performed as previously published [45, 46]. In
brief, spheroids were washed in saline before being resuspended
Figure 1. Generation of human pluripotent stem cell-derived hepatocytes and their therapeutic potential in various model systems. (A):
Four-stage hepatic differentiation from human pluripotent stem cells (hPSC) to definitive endoderm, hepatic endoderm, and subsequently
hepatocytes (hPSC-Heps) over a 21-day protocol by a defined cocktail of growth factors and small molecules (in the box). (B): Schematic
of further maturation of hPSC-Heps in two-dimensional culture dish coated with type I collagen, three-dimensional (3D) inverse colloidal
crystal scaffold coated with type I collagen (inverse colloidal crystal) and encapsulation within 3D alginate microspheres.
© 2018 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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into a final 1.8% ultra-pure low-viscosity, high-glucuronic acid
(≥60%), sodium alginate (FMC BioPolymer, Drammen, Norway)
solution, which was then delivered by syringe pump through a
0.2 mm diameter nozzle, from which droplets were electro-
statically deposited into a divalent cationic solution (1 mM
BaCl2 + 50 mM CaCl2) to cause gelation.
Live/Dead Staining
Fluorescine diacete (FDA; Sigma–Aldrich) and cell-impermeant
ethidium homodimer-1 (EthD-1; Thermo Fisher Scientific) were
used as recommended by the supplier for staining of viable
and dead cells. Spheroids and alginate encapsulated cells were
incubated in 4 μM EthD-1 for 35 minutes, washed with Hank’s
Balanced Salt Solution (HBSS) containing calcium (Thermo
Fisher Scientific), then incubated in 50 μg/ml FDA for 90 sec-
onds, and finally washed five times with HBSS before imaging
on a Leica TCS SP8 Confocal laser scanning microscope (Leica
Microsystems, Wetzlar, Germany).
Transplantation of hPSC-Derived Hepatocyte Spheroids
Alginate microencapsulated hepatocyte spheroids were intra-
peritoneally xenotransplanted into immune competent (C57BL/6
and Crl:CD1 [CD-1]) and immune deficient (Rag2γ) mice. Spher-
oids were cultured in vitro for 3 days (CD-1) or 7 days (C57BL/6
and Rag2γ) prior to encapsulation, and incubated within
RPMI-1640 medium for 2 hours before transplantation. Empty
cell-free microspheres were transplanted as a control. Surgical
procedures were carried out under isoflurane anesthesia (1%–
5% isoflurane, 95% oxygen, 1 l/min), with 30 μg/kg buprenor-
phine being administered immediately postsurgery. To create a
sterile site of surgery, the mouse abdomen was shaved and
cleaned with both antiseptic iodopovidone and isopropyl
alcohol. A small incision through the skin, and a subsequent
through the linea alba of the peritoneum allowed saline
suspended alginate microspheres, containing approximately
2 × 103 hepatocyte spheroids, to be delivered into the perito-
neal cavity using a sterile pipette.
Recovery of hPSC-Derived Hepatocyte Spheroid
Containing Microspheres
The mice were sacrificed by subcutaneous pentobarbital
euthanasia 72 hours after transplantation. Blood samples were
collected through cardiac puncture, and serum was diluted
1:10 for the detection of human albumin by ELISA. Injection of
5 ml saline into the peritoneal cavity was performed so that
microspheres could be collected by peritoneal lavage. Micro-
spheres were washed in saline and then maintained on ice,
in RPMI-1640 medium, until further analyses could be
performed.
Immunohistochemical Staining
Recovered microspheres were first fixed with 4% paraformalde-
hyde for 15 minutes, washed four times using PBS and trans-
ferred into 70% ethanol. The dehydrated samples were then
paraffin infiltrated using Excelsior AS Tissue Processor (Thermo
Fisher Scientific) and paraffin embedded using HistoStar Embed-
ding Workstation (Thermo Fisher Scientific). Five micrometres
thickness slides were then sectioned ready for immunohisto-
chemical staining with a mouse and rabbit specific horseradish
peroxidase/3-amino-9-ethylcarbazole (HRP/AEC) detection immu-
nohistochemistry (IHC) kit (Abcam, Cambridge, U.K.).
RESULTS
We firstly recovered two lines of hiPSCs, as well as one line of
hESCs, each of which having been derived independently
using cGMP-compliant protocols. We maintained all lines in iden-
tical culture conditions comprising of xeno-free cell culture matrix,
Vitronectin, and chemically defined pluripotency culture
medium, TeSR-E8. After several passages within these culture
conditions, each of the lines had fully reconditioned, with
comparable cell morphologies and colony sizes (Supporting
Information S1); each line producing characteristic rounded col-
onies, with small densely packed cells. We then began investi-
gating the capability of each line in producing high quality
hPSC-Heps using an adapted four-stage hepatocyte differentia-
tion protocol based on Hannan et al. [47], and their potential
application in downstream clinical applications by achieving
advanced phenotypes in macroporous hydrogels and ensuring
viability within transplantation ready cell encapsulation models
for ALF therapy (Fig. 1).
Differentiation of cGMP-Compliant Stem Cells Toward
hPSC-Derived Hepatocytes
To prepare for hepatic differentiation, we seeded fragmented
hPSC colonies obtained through enzyme-free dissociation with
minimal trituration onto gelatin coated tissue culture dishes. We
treated hESCs with the small molecule Y-27632 dihydrochloride,
an inhibitor of the RHO/ROCK pathway, overnight to ensure suffi-
cient cell attachment onto the gelatin. We found that the hiPSC
lines did not require the addition of this small molecule to be
passaged, or adhere to gelatin. We then initiated hepatic differ-
entiation 2 days postseeding; having allowed enough time for
the hPSCs to reestablish rounded colonies, with the outer cells
tending to have a larger, more spread morphology.
We closely monitored the morphology of the cells through-
out the differentiation and cross-compared against that of our
previous publication, that used non-cGMP-compliant hiPSCs, to
ensure appropriate differentiation was achieved (Fig. 2A). Upon
differentiation, the clear borders signifying stem cell colonies
dissipate gradually with the peripheral cells starting to spread
and migrate out sporadically by day 1 postdifferentiation. These
protruding cells expand in size and proliferate to close the
space between neighboring colonies until a confluent mono-
layer is formed by day 4. At this stage, cells exhibit definitive
endoderm (DE)-like morphology which persists until the media
condition is changed to contain oncostatin-M and hepatocyte
growth factor at day 9. After this alteration, the morphology
becomes more dynamic as the cells continue to differentiate.
By day 14 the cells start to transform from their elongated mor-
phology, observed at day 11, into a more cuboidal shape. The
signature, well defined, polyhedral morphology of hepatocytes
is observed across the whole culture by day 17. As demon-
strated by the dynamic morphological transformation through-
out the course of differentiation, all three of cGMP-compliant
lines appear capable of generating populations of DE, hepatic
endoderm, and subsequently hPSC-Heps (Fig. 2B).
Characterization of cGMP-Compliant hPSC-Derived
Hepatocytes
We next validated that the cGMP-hPSCs were differentiating
through the correct developmental lineage trajectory by
www.StemCellsTM.com © 2018 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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collecting the cells and quantifying their mRNA expression at
four distinct stages of the protocol (Fig. 3A). These time-points
represent undifferentiated hPSCs, DE (day 7), hepatic endo-
derm (HE, day 14) and finally hPSC-Heps (day 21).
Importantly the expression of NANOG, a key pluripotency
gene, is significantly downregulated upon differentiation, and
is obsolete at day 21, the stage in which hPSC-Heps have been
produced. Furthermore, the expression of both CXCR4 and
SOX17, well established markers for both DE and primitive
endoderm, are found to peak and be significantly upregulated
at day 7 of differentiation when compared with undifferen-
tiated hPSCs; after this time-point the expression of both
genes dissipates. To assess the correct differentiation into
hPSC-Heps, we selected six major hepatic genes for investiga-
tion. By day 21 a significant increase in the relative expression
of AFP, can be measured. AFP is the gene encoding α-fetopro-
tein, a major plasma protein produced by the developing liver
and considered to be the fetal version of albumin [48]. Inci-
dentally, expression of ALB, albeit not significant, is detected
at days 14 and 21 of differentiation, with the expression
being greatest at the later time-point. This provides evidence
that at this stage the cell type produced is one that resembles
a maturing hepatocyte. In addition, the relative gene expres-
sion for HNF4A, a hepatic transcription factor, as well as
ASGR2 (day 21 only), which encodes an asialoglycoprotein
receptor isoform primarily found on liver cells, are signifi-
cantly higher than that of undifferentiated or DE cells. In the
case of HNF4A, the relative gene expression is peaked at day
14, indicative that the hepatocyte-fate determination has
occurred. Moreover, the expression for SERPINF2, the gene
encoding the serpin α-2 antiplasmin which is secreted in
plasma by hepatocytes, is significantly elevated after 21 days
of differentiation. Finally, nonsignificant, but elevated expres-
sion of CYP3A7 is detected in day 21 hPSC-Heps than the ear-
lier time-points. This cytochrome P450 3A family isoform is
predominately expressed in the developing liver, with the
translated enzyme involved in the metabolism of drugs, together
with the synthesis of cholesterol, and various other lipids.
After validating the hepatic specific morphology and gene
expression, we next sought to characterize the population
profiles of the cells generated using our adapted protocol
by performing flow cytometry analysis on day 21 hPSC-Heps
Figure 2. Morphological characterization of hepatic differentiated cells. (A): Brightfield microscopy images revealing the morphological
transformation from day 0 pluripotent stem cell colony to day 17 polyhedral hepatocytes. (B): Representative images of day 21 human
pluripotent stem cells-Heps generated from three different current good manufacturing practice-compliant lines. Scale bars: 100 μm.
© 2018 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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(Fig. 3B). The hepatic progenitor markers EpCAM (98.1%) and
cytokeratin-19 (58.8%) were expressed on most cells analyzed.
In addition to these hepatic progenitor markers, expression of
the asialoglycoprotein receptor 1 (ASGPR1), an endocytotic
cell surface receptor specific to adult hepatocytes, was
detected on 41.3% of day 21 hPSC-Heps. The presence of
hepatocyte progenitor markers and nonsignificant gene expression
of ALB and CYP3A7 displays the need for further maturation
culture to produce a cell more closely resembling an adult
hepatocyte.
2D Maturation of hPSC-Heps
Having validated that cGMP-compliant hPSCs were able to gen-
erate cells resembling immature hepatocytes when cultured in
Figure 3. Phenotypical characterization of hepatic differentiated cells. (A): Differential expression of selected genes reveals progressive
maturation of human pluripotent stem cells (hPSCs) to definitive endoderm, hepatic endoderm and then hepatocytes (hPSC-Heps).
Expression relative to the housekeeping gene, and normalized against the average expression of hPSCs; n = 3 experiments, 1 cell line.
Data are mean  SEM, ordinary one-way ANOVA followed by Dunnett post hoc test to compare the mean of each group to hPSC expres-
sion. **, p < .005; ***, p < .0005; ****, p < .0001; ns: nonsignificant. Data shown for cell line 1. (B): Flow cytometry analysis of surface
marker expression on hPSC-Heps at day 21 of differentiation. Data shows the percentage of positive cells from the live cell population.
Gray histogram represents fluorescence minus one (FMO) control used to establish the gate, red histogram represents stained hPSC-Heps.
All flow cytometry analysis is representative of at least three independent experiments. Data shown for cell line 3.
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our differentiation conditions, we next aimed to advance their
hepatic maturation through culturing the cells within different
culture model systems to challenge the clinical relevance of our
protocols. We first seeded the day 21 hPSC-Heps onto collagen-
1 coated tissue culture plastic, as it is an extracellular protein
that has been shown capable of supporting the long-term cul-
ture, and liver-specific functions, of isolated adult hepatocytes
[49]. Upon seeding, the hPSC-Heps recovered their polyhedral
morphology within 2 days. It should be noted that if not seeded
to confluence, then many cells do not remain viable in 2D cul-
ture on collagen-1, and those remaining do not proliferate, or
go on to develop a mature phenotype.
After 3 weeks of maturation culture on collagen-1 coated
tissue culture plastic, we performed immunofluorescent stain-
ing to assess the hepatic maturity and heterogeneity of the
hPSC-Heps (Fig. 4A). Firstly, none of the pluripotency or endo-
dermal markers, such as OCT4 and CXCR4 are detected in the
cultures, which is a good indicator that the conversion of stem
cell to hepatic lineage cell was completed in our protocol. It is
encouraging to observe hepatocyte-specific markers, for exam-
ple the nuclear transcription factor, HNF4α and protease
inhibitor, A1AT, to be abundantly expressed throughout the
cultures. To further delineate the maturity of hPSC-Heps cul-
tured on collagen-I coated 2D surfaces, we assessed the pres-
ence of hepatoblast specification (AFP, KRT19, and EpCAM)
and hepatocyte specification (ALB and ASGPR1) markers,
respectively. We found that even though the expression of
mature markers, such as ALB and ASGPR1, are prevalent
across the culture, we still observed substantial regions of cells
that expressed AFP, KRT19, and EpCAM. The perseverance of
these progenitor markers reveals a potential limitation of 2D
culture in terms of differentiating a fully adult-like hepatocyte.
Of note, zona occluding 2 (ZO-2), a component of tight junc-
tion proteins was highly expressed in 2D culture, highlighting
the polyhedral morphology of the cells.
For a broader evaluation of the maturation of hPSC-Heps
in 2D, we compared the mRNA expression of cells 20 days
postseeding to that of the preseeding population (Fig. 4B). A
significant reduction in the level of AFP is achieved, while con-
versely, a significant enhancement in ALB expression occurs. A
similar significant 15-fold increase is found in the relative
expression of CYP3A7 after the additional 20 days of culture.
Interestingly, although enzyme activity was measurable in the
previous assay, the gene expression of CYP3A4 is elevated, but
not significantly higher than that of the preseeding population.
These mRNA expression results corroborate with our immu-
nostaining observation that our cells are yet to achieve
advanced maturity in this 2D model system.
To characterize the liver specific functions of the cells, we
monitored the albumin production rate (Fig. 4C and Supporting
Information S2) and the metabolic activities of the cells over an
extended period (Fig. 4D). As a 2D monolayer, hPSC-Heps
secreted albumin at levels detectable by ELISA after 6 days post-
seeding. Once cultured for a further week, the amount of albu-
min protein measured was significantly higher and an indicator
of a maturing phenotype. Moreover, the albumin production is
comparable between the three lines assessed, with no signifi-
cant differences measured after 8 or 14 days of maturation. Fur-
thermore, when cultured for an additional week (20 days
postseeding), noninduced enzyme activity of cytochrome P450
3A4 can be detected (Fig. 4D). For each of the three lines, the
enzyme activity detected is significantly greater at 20 days post-
seeding when compared with that of those after just 8 days.
Again, no significant difference between the different cGMP-
compliant lines was measured at either time-point, nor was
activity detected in hPSC-derived cells prior to 2D maturation
culture. The presence of CYP3A4 activity, which is initially absent
from the liver of new-borns, and responsible for >50% of medici-
nal drug metabolism, is a clear indicator that the extended cul-
ture period results in matured hepatocytes [50, 51].
3D Maturation of hPSC-Heps Within a PEG-DA-Based
Scaffold Suitable for Biomedical Applications
Having achieved considerable maturation on 2D collagen-1
coated tissue culture plastic, we proceeded to load day
21 hPSC-Heps into a more physiologically relevant model sys-
tem for advanced hepatic maturation. We used a 3D macro-
porous PEG-DA hydrogel, known as an inverse colloidal crystal
(ICC) scaffold, that aims to mimic the anatomy of native liver
tissue. The ICC scaffold has uniform sized pores, intercon-
nected in a hexagonal pattern, and we have previously demon-
strated the generation of liver organoids using both primary
human fetal liver cells [52] and non-cGMP-compliant hPSCs
[53] within this model. To facilitate the characterization of the
morphogenic transformation of hPSC-Heps within this scaffold,
we performed a series of immunofluorescence staining and
constructed the 3D images using confocal microscopy. Firstly,
we observed that upon seeding into the ICC hydrogel, hPSC-
Heps establish cell-matrix interactions with the coated ECM
protein and achieve confluence over the concave surface of
the internal pores of the scaffold within 3–5 days postseeding
(Fig. 5A). Within 7 days postseeding, the cells self-assemble
into mechanically stable interconnected clusters that resemble
organoid structures for up to at least 3 weeks in culture. These
distinct phases of morphogenesis were further illustrated with
immunofluorescence imaging of beta-catenin (CTNNB1) and
keratin 18 (KRT18) staining. Keratin 18 is the major intermedi-
ate filament protein in the liver, with a role in regulating glu-
cose metabolism and modulating insulin signaling [54],
whereas beta-catenin is the central constituent of canonical
Wnt signaling and is implemented as a fundamental regulator
in hepatic physiology and development [55].
To further evaluate the phenotype of hPSC-Heps within this
ICC culture model, we selected additional hepatic specific
markers, along with markers of hepatocyte polarity, for broader
evaluation by immunofluorescence imaging. Closer inspection on
confocal micrograph revealed that the self-assembled intercon-
nected clusters inside the ICC scaffold consisted of a heteroge-
neous population, with AFP positive liver progenitor cells
occupying the periphery of the cluster and surrounding the ALB
positive mature hepatocytes at the core (Fig. 5B). As most cells
of the organoid-like clusters stained positive for cytoplasmic
albumin, amid only few positive for AFP, this staining served as
confirmation that the seeded hPSC-Heps go on to develop a
more mature phenotype. Moreover, correctly localized expres-
sion of the tight junction proteins ZO-1, ZO-2, occludin and
claudin-1, bile-salt efflux pump (BSEP) and dipeptidyl peptidase-4
(CD26) were observed. These proteins are key components of
bile canaliculi that form between the lateral faces of hepatocytes,
and merge into bile ductules. The performed immunofluores-
cence staining provides validation of the liver-specific signature
of the organoid-like structures generated.
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We then performed a series of characterization to interro-
gate whether seeding hPSC-Heps into this 3D environment
resulted in the acquisition of greater maturity compared with
the 2D culture model. RT-PCR revealed that the expression of
mature hepatic genes for proteins involved in biosynthesis
(ALB), glycoprotein homeostasis (ASGR2) and metabolic functions
Figure 4. Characterization of human pluripotent stem cells (hPSC)-derived hepatocyte maturation in two-dimensional (2D) model. (A):
Immunofluorescent images revealing the transition of pluripotency (OCT4), endodermal (CXCR4), and hepatic specification (HNF4A, A1AT,
AFP, KRT19, and EPCAM) and mature hepatic (ALB, ASGPR1, and ZO-2) expression in hPSC-Heps after 20 days postseeding on 2D model.
Representative images selected from each of the three lines. Scale bar: 100 μm. (B): Differential gene expression showing the relative
expression of four key hepatic genes (AFP, ALB, CYP3A7, and CYP3A4) in preseeding (pre) and 20 days postseeding (20 dps) into 2D model.
Statistical significance determined by Student’s t test (two-tailed); n = 3 experiments. Data shown for cell line 1. Data are mean  SEM,
*, p < .05; **, p < .005; ns: nonsignificant. (C): Albumin production rate of hPSC-derived hepatic endoderm (HE), and hPSC-Heps 8 and
14 days postseeding (8 and 14 dps) into 2D model; n.d.: not detected; n = 6 experiments per cell line. Data are mean  SD, ****,
p < .0001. (D): Cytochrome P450 3A4 enzyme activity of hPSC-derived HE, and hPSC-Heps 8 and 20 days postseeding into 2D maturation cul-
ture, n.d.: not detected; n = 3 (mean luminescence value [n = 6] of 3 independent experiments). Data are mean  SD, ****, p < .0001.
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Figure 5. (Legend appears on next page.)
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(CYP3A7 and CYP3A4) were significantly upregulated in the cells
cultured within ICC scaffolds compared with those in 2D
(Fig. 5C). Notably, the expression of fetal hepatocyte associated
AFP was significantly higher in the 3D culture, however, this level
is still significantly lower than in the day 21 cells initially seeded
into the scaffold (Supporting Information S3).
Likewise, functional assays for albumin secretion (Fig. 5D)
and CYP3A4 enzyme activity (Fig. 5E) showed significant improve-
ments for hPSC-Heps matured within the ICC scaffold when
compared with their 2D counterparts. The attainment and
enhancement of these cellular functions are both major fea-
tures of advanced hepatic differentiation, and their presence
would be an unconditional necessity for any potential stem
cell-derived therapy. Cumulatively, these data confirm that
cGMP-compliant hPSC-derived hepatocytes can successfully be
matured into a functional hepatic phenotype within a 3D, read-
ily up-scalable, system. This combination of cGMP-compliant
cells and a biocompatible scaffold not only provides a platform
conducive to the further study of hPSC-Heps, but could also
hold potential for future drug development and safety studies,
and for assisting as a vehicle for cell transplantation.
Generation of Alginate Encapsulated Hepatocyte
Spheroids
To assess the broader translational potential of cGMP-
compliant hPSC-derived hepatocytes for cell-based therapies
aimed at ALF, we carried out microencapsulation of hPSC-Heps
within alginate; a methodology that allows transplanted cells
to be isolated from the recipient’s immune responses [56].
Successful encapsulation of hepatocytes within alginate hydro-
gels has been reported [57]. However, to reduce the possibility
of cell death during the encapsulation process [58], we used
an additional established culture model, spheroid culture [59];
known to both prolong viability [60] and phenotypes of hPSC-
Heps [61] (Supporting Information S4).
To generate spheroids for encapsulation (Fig. 6A), we used
nonadherent microwell containing plates, called AggreWell,
which have previously been used to generate spheroids from
hiPSCs [62]. We centrifuged single cell suspensions of hPSC-
Heps into microwells to facilitate cell–cell interactions for
spheroid formation in large readily scalable quantities (Fig. 6B).
The spheroids were left in culture for 7 days prior to encapsula-
tion within 1.8% alginate microspheres. The 3D aggregates
maintain their structure and uniformity as they are pumped
through the microcapsule generator’s 0.22 mm diameter nozzle
at a rate of 10 ml/hour. The crosslinking of alginate occurs in
under 5 minutes within barium chloride/calcium chloride solu-
tion, with most microspheres containing a single spheroid. We
then washed the collected microspheres in saline and subse-
quently placed back into HepatoZYME-SFM. To ensure that the
viability of these hPSC-Heps was preserved throughout this pro-
cess, we carried out live/dead immunofluorescence staining
using FDA and ethidium homodimer-1 (EthD-1) 6 hours after
the encapsulation (Fig. 6C). Confocal microscopy confirmed
that both alginate- and noncapsuled spheroids contain minimal
to no dead cells (EthD-1 stained nuclei), with close to all cells
having hydrolysed FDA into fluorescent fluorescein. Further-
more, encapsulation does not impact the viability of hepato-
cyte spheroids placed back into further culture (Supporting
Information S5).
To test the clinical suitability of alginate encapsulated
hPSC-Heps as a bridging therapy for ALF, we xenotrans-
planted spheroid containing microspheres into the peritoneal
cavity of immune competent C57BL/6 and CD-1 mice, as well
as immune deficient Rag2γ mice. We monitored transplanted
mice over a period of 12 days, and no signs of postoperative
complication or mortality were observed. Blood sera col-
lected from mice 3 days postprocedure revealed that the
cells remain functional upon transplantation as the presence
of human albumin (Fig. 6D) was detected by ELISA in all ani-
mals having received microspheres containing cGMP-hPSC-
derived hepatocyte spheroids. Additionally, we recovered
transplanted microspheres at this time-point to evaluate
in vivo cell survival and hepatic phenotype preservation.
Microspheres were found dispersed throughout the perito-
neal cavity with no sign of bruising, inflammation, or fibrosis
(Supporting Information S6A). Upon closer inspection, we
observed that microspheres recovered from each mouse
strain had remained mechanically intact in vivo, and detected
no sign of host cell invasion into the alginate (Supporting
Information S6B); demonstrating that the encapsulation had
served as an effective barrier. Most importantly, the viability
and hepatic phenotype of transplanted spheroids was pre-
served in vivo throughout the critical therapeutic window for
an ALF bridging therapy. Live/dead immunofluorescence
staining of recovered spheroids revealed a minimal number
of nonviable cells (Fig. 6E), comparable to that of encapsu-
lated cells maintained in vitro (Supporting Information S7).
We performed immunohistochemical staining on recovered
microspheres that confirmed that the encapsulated hepato-
cyte spheroids had remained positive for human KRT18 and
ALB. Staining with STEM121 that reacts specifically to a
human cytoplasmic protein, known to be expressed in vari-
ous tissues including the liver, further confirmed that cells
present within the microspheres were of human origin.
Moreover, antibodies against murine CD45 revealed no host
Figure 5. Characterization of human pluripotent stem cells (hPSC)-derived hepatocyte maturation within three-dimensional (3D) inverse
colloidal crystal (ICC) model. (A): Immunofluorescent confocal images of hPSC-Heps demonstrating two distinguished morphological
phases inside the ICC scaffold. Three days postseeding an adhered lining across the hydrogel pores is observed, before the hPSC-Heps
morph into interconnected 3D clusters from 7 days postseeding onward. Arrowheads indicate cells lining the ICC scaffold surface; aster-
isks represent cells forming 3D clusters. Scale bar, 100 μm. (B): Immunofluorescent confocal images highlighting hepatic (AFP and ALB)
and polarity (ZO-1, ZO-2, OCLN, CLDN1, BSEP, and CD26) proteins known to be present in adult human hepatocytes. Scale bar, 100 μm.
Staining was performed on cell clusters after hPSC-Heps had been cultured for 2 weeks in 3D. (C): Real-time polymerase chain reaction
showing the relative expression of five major hepatic genes (ALB, ASGR2, CYP3A4, AFP, and CYP3A7); n = 4 experiments, one cell line.
(D): Albumin production rate of hPSC-Heps cultured in 2D versus ICC models; n = 4 experiments, one cell line. (E): CYP3A4 basal activity
of hPSC-Heps cultured in 2D versus ICC scaffolds; n = 4 experiments, one cell line. Data are mean  SD. Student’s t test (two-tailed) anal-
ysis. **, p < .005; ***, p < .0005; ****, p < .0001. Data shown for cell line 1.
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Figure 6. Generation of alginate encapsulated hepatocyte spheroids suitable for acute liver failure bridging therapy. (A): Schematic illus-
trating the high throughout generation of uniform hepatocyte spheroids made up from around 250 human pluripotent stem cells (hPSC)-
Heps using multi bioinert V-bottom microwells and electrostatic alginate microsphere encapsulation within a BaCl2 and CaCl2 solution
bath. (B): Brightfield images showing hepatocyte spheroids inside AggreWell microwells and alginate microsphere encapsulated spheroids.
(C): Confocal images revealing the live/dead staining of hPSC-Heps as hydrogel-free spheroids, and within alginate microspheres, 6-hours
post encapsulation. (D): Human albumin detected within the blood serum of mice intraperitoneally xenotransplanted with alginate micro-
spheres containing hepatocyte spheroids. (E): Confocal images revealing the live/dead staining of spheroids within microspheres recov-
ered 3 days post-transplantation. (F): Immunohistochemical staining of recovered microspheres showing cells positive for human hepatic
markers (hKRT18 and hALB) human specific STEM121, and negative for murine/host immune marker (mCD45) at day 3 post-transplanta-
tion. Data shown for cell line 2. Scale bars, 100 μm.
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cell infiltration within the alginate (Fig. 6F and Supporting
Information S8). Overall, this proof-of-concept study together
with our recent publications on in vitro [63] and in vivo [64]
alloimmune studies suggests that microspheres encapsulating
cGMP-compliant hPSC-Heps are both safe and effective for
cell-based therapies aimed at ALF.
In summary, we report that a library of cGMP-compliant
hPSCs can be differentiated into hepatocytes by a chemically
defined protocol, which is suitable for clinical implementa-
tion. We confirm that this development goes via an
endoderm-like stage, before immature hepatocytes are
obtained after 3 weeks. When matured by further culture in
either 2D, or 3D models, these hPSC-Heps express proteins
known to be present on adult hepatocytes, have improved
hepatic gene expression, and go on to demonstrate key liver
functions.
DISCUSSION
The manufacture of cGMP-compliant hPSC lines and optimiza-
tion of translationally relevant differentiation technologies, is
essential for clinical application of hPSCs [65]. We have, to our
knowledge for the first time in this report, validated that a
library of clinical grade cGMP-hPSC can successfully be differ-
entiated into hepatocytes in a chemically defined protocol.
Cells generated in this way demonstrated genes, proteins, and
hallmark functional characteristics of hepatocytes, but as
shown by us and others previously [66], fell short of the
benchmarks set by primary adult cells. By subsequently seed-
ing these immature hepatocytes into bio-engineered 3D scaf-
folds fabricated from FDA approved material, we were able to
drive the cells into liver tissue functionally approximated to
the standard needed for clinical efficacy.
Following maturation within our 3D scaffold, elevated expres-
sion of key hepatic genes, such as ALB, CYP3A7, and CYP3A4 for
example were all found to occur. CYP3A7 was first deemed as
being exclusively expressed in the developing fetal liver [67], but
it is now known to be present in up to 88% of adult livers [68,
69]. This elevation in expression is of importance because cyto-
chrome P450 enzymes are essential for the metabolism of numer-
ous endogenous compounds and drugs. The CYP3A sub family
specifically makes up 30% of the adult liver’s cytochrome P450
constituency [70] and metabolize half of marketed drugs [71].
Importantly, the level of CYP3A4 enzyme activity is also elevated
in hPSC-Heps within 3D ICC culture when compared with 2D; as is
the albumin production rate of the cells. It is also important to
highlight that the upregulation in hepatic functions, and the
organoid-like morphological transformation observed in cGMP-
compliant hPSCs, are well aligned with our previous 3D study
using a more well-established non-cGMP-compliant hiPSC line
[53]. The unique fabrication technique of our scaffold permits the
scale-up of this cell-scaffold complex—up to containing the bil-
lions of cells required for human translation—and can be functio-
nalized with different recombinant proteins, molecules or
mechanical parameters. Cumulatively, these design features sug-
gest such a scaffold could be the ideal carrier for delivering
cGMP-compliant hPSC-Heps into patients.
Assuming delivery of suitable numbers of functionally opti-
mized cGMP cells can be achieved as above, a further challenge
for clinical application will be to deal with the potential allogenic
immune rejection of the host [72]. Alginate hydrogel microen-
capsulation provides hPSC-derivatives with a physical barrier
from the recipient’s immune system, through enclosure within a
naturally occurring anionic polymer. Alginate, typically obtained
from brown algae, is considered ideal for biomedical applica-
tions due to its biocompatibility, low cost, and ease of gelation
[73]. Numerous cell types have successfully been encapsulated
within alginate, including mesenchymal stromal cells [74], pan-
creatic islets [75], and human hepatocytes [76], while optimized
GMP grade alginate encapsulation protocols have already been
established for the transplantation of human hepatocytes to
provide metabolic function in patients with ALF [63].
Status 1 ALF failure patients are assessed as having a life
expectancy of hours, to a few days, without a liver transplanta-
tion [77]. The median number of days from status 1 listing to
death is just 5.5 with over a fifth of adults dying on the waiting
list [78]. The condition of patients with ALF can change signifi-
cantly, even within 72 hours of being listed for transplantation
[79] with 13.9% of patients requiring “superurgent liver trans-
plantation” due to ALF having a spontaneous recovery [80].
These clinical reports support the hypothesis that ALF is poten-
tially reversible without the need for transplantation if the host
liver can be given enough time to recover. Our study demon-
strated cGMP-derived hepatic constructs remained viable, and
more importantly, functional within the peritoneal cavity of
fully immune competent C57BL/6 and CD-1 mice for a time
period long enough to result in recovery from ALF if used in
patients. This in turn strongly advocates for further develop-
ment of hPSC-hepatocytes as a clinical therapeutic [63, 81–83].
CONCLUSION
We report here a library of clinical grade hPSCs manufactured
under cGMP conditions amenable to reproducible hepatic dif-
ferentiation, 3D culture, and alginate encapsulation that is
potentially suitable for human application.
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